# MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

> **NCT00833833** · PHASE1,PHASE2 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 259 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT00833833
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2011-04
- **Final completion:** 2015-09
- **Target enrollment:** 259 (ACTUAL)
- **Last updated:** 2016-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00833833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00833833, "MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00833833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*